Quantum Genomics Société Anonyme ( ALQGC.PA) Stock. Should you Buy or Sell? $ 1.92
0.00 (-0.31 %)
Quantum Genomics Société Anonyme Analysis
Updated on 03-07-2022
|52 Week Range
||$1.541 - $6.185
Quantum Genomics Société Anonyme opened the day at $1.92 which is -0.31 % on yesterday's close.
Quantum Genomics Société Anonyme has a 52 week high of $6.185 and 52 week low of $1.541, which is a difference of $4.644.
We like to see positive, upward trending shares, preferably with momentum.
Market capitalization is $52.6 M and total net profit is $116211 which means the company is trading at 452.61 times profit to market capitalization. Theoretically, if you were to buy Quantum Genomics Société Anonyme for $52.6 M, it would take 15 years to get your money back. Quantum Genomics Société Anonyme are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
1 D | All
Quantum Genomics Société Anonyme Stock Forecast - Is Quantum Genomics Société Anonyme a Buy or Sell?
|DCF Score||Strong Buy|
|PE Score||Strong Sell|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin
Valuing Quantum Genomics Société Anonyme
|Price Book Value Ratio
||Price To Book Ratio
|Price To Sales Ratio
||Price Earnings Ratio
How liquid is Quantum Genomics Société Anonyme
||Debt Equity Ratio
|Long Term Debt To Capitalization
||Total Debt To Capitalization
Latest news about Quantum Genomics Société Anonyme
About Quantum Genomics Société Anonyme
CEO : Mr. Lionel Segard
Sector : Healthcare
Industry : Biotechnology
Website : https://www.quantum-genomics.com
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.